<track id="ine19"><span id="ine19"></span></track>
<source id="ine19"></source>
<bdo id="ine19"><optgroup id="ine19"></optgroup></bdo>

      Zai Lab has a broad and validated late-stage pipeline in oncology and infectious disease. We currently have 2 products commercialized and 4 drugs approved in the U.S. (marked with * below). Overall, our pipeline consists of over 15 drug candidates with over 20 ongoing or planned clinical trials.

      Oncology
      Molecule Name
      Potential Indication
      Phase
      Pre-clinical
      Phase I
      Phase II / POC
      Phase III / Pivotal
      NDA Filed
      Marketed
      Ovarian Cancer (2nd line maintenance) *
      Mainland China, HK & Macau (China)
      Ovarian Cancer (1st line maintenance)*
      Mainland China
      Ovarian Cancer (late line treatment)*
      Gastric Cancer (I/O[3] combo)[1]
      Other solid tumors[2] (I/O[3] combo)
      Glioblastoma (GBM) *
      Hong Kong (China), mainland China
      Mesothelioma* (Optune Lua)
      NSCLC[4]
      Brain Metastases from NSCLC
      Pancreatic Cancer
      Ovarian Cancer
      Gastric Cancer[1]
      Liver Cancer
      GIST[5] (4th Line)*
      GIST[5] (2nd Line)
      Systemic mastocytosis
      B-NHL - r/r FL, r/r DLBCL, r/r MCL, r/r MZL, etc. [6, 7]
      ROS1+ NSCLC[4], NTRK+[8] solid tumors
      HER2+ Breast Cancer
      HER2+ Gastric/GEJ Cancer[9] (combo[10])
      Gastric/GEJ Cancer[9]
      EGFR ex20ins NSCLC
      MET+ NSCLC and GC
      Hepatocellular carcinoma (HCC) (combo with brivanib)
      Melanoma[1]
      Basket trial
      NSCLC[11]
      MSI-high Endometrial[7]
      Multiple tumor types
      Multiple tumor types
      Oncology
      Oncology
      Oncology
      Oncology and autoimmune disease
      No data!
      No data!
      Infectious Disease and Autoimmune
      Molecule Name
      Potential Indication
      Phase
      Pre-clinical
      Phase I
      Phase II / POC
      Phase III / Pivotal
      NDA Filed
      Marketed
      No data!
      No data!
      No data!
      No data!
      No data!
      No data!
      No data!
      No data!
      Acute Bacterial Skin and Skin Structure Infection (ABSSSI) *
      Community-Acquired Bacterial Pneumonia (CABP) *
      A.Baumanii Bacterial Infections
      Generalized Myasthenia Gravis
      Immune Thrombocytopenic Purpura
      PV, CIDP
      Psoriasis, etc.

      Note: [1]  China-only trials;  [2] Including non-small cell lung cancer; [3] Immuno-oncology; [4] Non-small cell lung cancer; [5] Gastrointestinal stromal tumors; [6] B-NHL, B-cell non-Hodgkin lymphoma; r/r, relapsed or refractory; FL, follicular lymphoma; DLBCL, diffuse large B-cell lymphoma; MCL, mantle cell lymphoma; MZL, marginal zone lymphoma; [7] Potentially registration-enabling trial; [8] Neurotrophic tropomyosin receptor kinase; [9] Gastroesophageal junction cancer; [10] Phase 2/3 study and registration path in first-line gastric & GEJ cancer; combo with retifanlimab and tebotelimab, respectively; [11] Non-small cell lung cancer; Phase 3 in preparation; [12] Bridging study ongoing.


      分分28